----
Current ValuationThe current P/E ratio is -14.87, above the reasonable range, cheaper than 15.31% of the time in the past 1 years, and the industry ranks 57/78, the industry Median -5.33.
-14.87xP/E
HK$18.81Stock price
HK$-1.26Earnings per share
-14.87xP/E
Stock priceHK$18.81Earnings per shareHK$-1.26
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -22.56x
- Typical range
- -56.44x–-16.45x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0157314471628
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -72.05x | 75.24% | HK$80.23B |
09688HKZAI LAB | -14.76x | 435.53% | HK$22.97B |
01877HKJUNSHI BIO | -35.06x | 83.59% | HK$16.11B |
07666HKMETIS TECHBIO-P | -31.93x | 96.67% | HK$13.00B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
06855HKASCENTAGE | -6.49x | 18.76% | HK$10.98B |
01952HKEVEREST MED | -154.35x | 326.79% | HK$9.58B |
09606HKDUALITYBIO-B | -5.77x | 85.35% | HK$9.55B |
02616HKCSTONE PHARMA-B | -17.69x | 1.09% | HK$8.54B |
02595HKGENFLEET-B | -5.49x | 66.07% | HK$8.31B |
02493HKMABWELL-B | -6.63x | -- | HK$8.11B |
06938HKRIBOLIFE-B | -37.42x | 29.56% | HK$7.31B |
09887HKLEADS BIOLABS-B | -23.66x | 3.57% | HK$7.27B |
02171HKCARSGEN-B | -63.02x | 52.33% | HK$6.47B |
02335HKMICOT PHARMA-B | -14.87x | 37.52% | HK$6.24B |
09966HKALPHAMAB-B | -29.80x | -- | HK$6.04B |
00775HKCKLIFE SCIENCES | -77.99x | -- | HK$5.05B |
01672HKASCLETIS-B | -7.03x | 78.53% | HK$4.79B |
02256HKABBISKO-B | -8.47x | 797.83% | HK$4.55B |
01779HKLONGBIO-B | -17.46x | -- | HK$4.35B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
